key: cord-0930077-uycm6evb
authors: Volpe, Massimo; Battistoni, Allegra
title: Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?
date: 2020-07-30
journal: Int J Cardiol
DOI: 10.1016/j.ijcard.2020.07.041
sha: 0c2151c36d0e2854bc8a4f4d175d126bd4542f84
doc_id: 930077
cord_uid: uycm6evb

A role for the renin-angiotensin-aldosterone-system in Severe Acute Respiratory Syndrome-Coronavirus-2 infection and in the development of COronaVIrus Disease-19 disease has generated remarkable concerns among physicians and patients. Even though a suggestive pathophysiological link between renin-angiotensin-aldosterone-system and the virus has been proposed, its pathogenic role remains very difficult to be defined. Although COronaVIrus Disease-19 targets preferentially older people with high prevalence of hypertension and extensive use of renin-angiotensin-aldosterone-system inhibitors, an independent role for hypertension and its therapies is not defined. In this article, we scrutinize evidence from the most representative available studies in which the potential role of renin-angiotensin system inhibitors, specifically angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, was evaluated in the COronaVIrus Disease-19 disease course, with regard to severity of the disease and mortality. We conclude that at this time, the overall available evidence fails to support a pathogenetic speaks against any harmful role for of renin-angiotensin-aldosterone-system inhibitors in COronaVIrus Disease-19. Consequently, we conclude that treatment with renin-angiotensin-aldosterone-system inhibitors should not be discontinued and, therefore, these therapies should not be interrupted.

The toll on people affected by COronaVIrus has exceeded 4 million with more than 300,000 victims in over 200 states worldwide [i] . The management of this pandemic has been different across countries, but it has implied everywhere a huge deployment of health and economic resources. From the first observations, it was evident that the incidence of this disease and its severity increases with age, male sex and the presence of comorbidities [ii] . Arterial hypertension is present in up to 50% of affected patients, in international case-series [iii] . Therefore, it has been speculated that one of the key pathophysiological mechanisms of hypertension itself, as well as anti-hypertensive therapies, could influence the development of Covid-19. In particular, the renin-angiotensin-aldosterone system (RAAS) seems to play a crucial role, since the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-Cov2) uses the angiotensin converting enzyme 2 (ACE2) to enter cells [iv] . On this basis, it has been initially proposed that angiotensin receptor blockers (ARB) and angiotensin converting enzyme inhibitors (ACEi), by increasing levels of ACE2 might favor SARS-Cov2 infection and therefore patients chronically treated with these therapies might present a more severe course of Covid-19. On the other hand, evidence from basic science and from pathophysiological data may suggest just the opposite since the blockade of angiotensin II is considered beneficial towards the pulmonary damage occurring during viral infections [v-vi] . Indeed, the chronic assumption of ARB, may protect patients against acute lung injury by blocking the deleterious effect of angiotensin II, such as vasoconstriction of lung vessels, increased pulmonary vascular permeability, inflammation and interstitial fibrosis, as well as by J o u r n a l P r e -p r o o f

We searched clinical papers investigating the effects of RAAS inhibitors on SARS-Cov2 infection and Covid-19 published during the last 90 days in English or at least with an abstract available in English, using as keywords "Covid 19"; "Sars-Cov-2"; "hypertension"; "angiotensin II"; "reninangiotensin-aldosterone system"; "angiotensin converting enzyme inhibitors"; "angiotensin receptor blockers" through Pubmed, with at least 50 patients enrolled.

Through the search, we retrieved sixteen eligible studies. All of them were retrospective casereports, totally involving more than 50000 Covid-19 cases. Four studies investigated the risk of develop Sars-Cov-2 infection [vii-viii-ix-x] , whereas others investigated the severity of the Covid-19 and death rate according to exposure to RAAS inhibitors. Most studies showed a neutral effect for ACEi/ARB on the primary outcome [7-8-9-10-xi-xii-xiii-xiv-xv-xvi-xvii-xviii], whereas six trials retrieved a protective effect for ACEi/ARB on primary or secondary outcomes [15-16-xix-xxxxi-xxii]; one study retrieved an increased risk in two secondary outcomes for patients taking ACEi/ARB [8] . Lately one study by Mehra et al [15] has been retracted because all the authors were not granted access to the raw data and the raw data could not be made available to a thirdparty auditor. Results are summarized on Table 1 .

Most studies available so far have been carried out in China, in relatively small population samples [7-11-14-16-21] . Across studies the definition of SARS-Cov2 infection is variable: in most cases, it is performed according to microbiology [8-9-12-13-17-20-21-22] , in one case only on chest computed tomography [20] ; whereas there is great variability in the definition of hypertension which is based on anamnestic data or on the blood pressure values found during hospitalization [7-8-10-13-17] . There is also variability in reporting the therapeutic regimen and its adherence from anamnestic data [17] [18] [19] [20] as well as prescription on hospital admission [17] [18] [19] [20] [21] . In this regards, J o u r n a l P r e -p r o o f Mancia's and De Abajo's recent works provide more detailed information on hypertension and its treatment [9] [10] [11] [12] [13] [14] [15] [16] [17] . In most studies, it is not explained whether hospitalized patients maintained their home therapy or not, nor it is stated whether blood pressure control was comparable in all groups of therapies [20] . Based on the results made available across all studies, it appears that hypertension, whose prevalence increases with ageing, is frequently associated with SARS-Cov2 infection, as well as with the development of a severe form of Covid-19 and with death, with one exception [19] .

Whenever analyzed, it appears that hypertensive patients on ACEi/ARB regimen at home are usually older and affected by more comorbidities [8-13-18], e.g. ischemic heart disease, heart failure and diabetes, chronic kidney disease and obesity which have not been consistently considered in multivariate analyses for outcomes, especially in earlier studies, but they might have heavily influenced retrieved outcomes. In spite of this heterogeneity of reports, we retrieved data from sixteen studies which globally showed no association between a chronic therapeutic regimen with ARB/ACEi and the infection by SARS-Cov2 [7-9-17], nor the development of more severe forms of Covid-19 or an increase in mortality in hospitalized patients [9-10-11-12-13-14-16-19-20-21] , except one single report, in which among patients with affected by COVID-19 those taking ACEI were more frequently admitted to the hospital and to an intensive care unit as well as those taking ARB were more frequently admitted to the hospital [8]. The bigger the circle, the largest is the sample enrolled in the corresponding study. ATI, angiotensin 1; ATII, angiotensin II; AT1R, type I angiotensin II receptors; AT2R, type II angiotensin II receptors; AT 1-9, angiotensin 1-9; AT 1-7, angiotensin 1-7; ACE, angiotensin converting enzyme; ACE2, angiotensin converting enzyme 2; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers.

• The SARS-Cov2 uses utilizes the angiotensin-converting enzyme 2 to enter cells

Renin angiotensin system inhibitors, increase angiotensin-converting enzyme II levels. • Therefore, these most common anti-hypertensive drugs might influence Covid-19

• Large series of data Extensive data that has recently become made available recently do not support this hypothesis

• The withdrawal of such We recommend that treatment with renin angiotensin system inhibitors is not recommended should not be discontinued in Covid-19 patients

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?

Epub ahead of print

Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China